Navigation Links
MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
Date:11/3/2008

GAITHERSBURG, Md., Nov. 3 /PRNewswire/ -- MedImmune today announced that it has initiated a Phase 1/2a clinical trial of a live, attenuated intranasal vaccine in healthy children one month to 12 months of age to help prevent severe respiratory syncytial virus (RSV) infections. RSV is the most common respiratory infection in infants and can cause disease in otherwise healthy infants and children.

"RSV is a serious respiratory disease that can have significant effects on children. As a leader in pediatric medicine, MedImmune is committed to developing therapies that can combat the most common cause of pediatric respiratory illness," said Filip Dubovsky, M.D., M.P.H, vice president, clinical development, vaccines. "Because respiratory illness due to RSV occurs in otherwise healthy children, developing a vaccine is a public health priority."

MedImmune is a world leader in the development of innovative therapeutic biologic products for prophylaxis and prevention of infectious diseases. This Phase 1/2a clinical trial is designed to assess the safety, tolerability, immunogenicity and viral shedding of the intranasal RSV vaccine in infants and young children. It is a randomized, double-blind, placebo-controlled and multi-dose study that will enroll 320 children.

The investigational vaccine, MEDI-559, is being developed through a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NAID), part of the National Institutes of Health, to help address RSV disease in children. The vaccine was originally developed in the NAID Division of Intramural Research by a team led by Peter L. Collins, Ph.D. and Brian R. Murphy, M.D.

About RSV

RSV is the most important cause of viral lower respiratory tract illness in infants worldwide. Each year, an estimated 125,000 infants in the United States are hospitalized with severe RSV infections. RSV is the most common respiratory infection in infancy or childhood that circulates in the Northern Hemisphere predominantly in the fall and winter months. Approximately one-half of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday.

About MedImmune

MedImmune is a leading innovation-focused biotechnology company whose mission it is to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular / gastrointestinal disease and neuroscience. Headquartered in Gaithersburg, Maryland, MedImmune has approximately 3,000 employees worldwide and is the wholly owned biologics business for AstraZeneca plc (LSE: AZN.L, NYSE: AZN). For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
2. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
3. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
4. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
5. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
6. The New England Journal of Medicine Publishes First Clinical Results for MedImmunes Chitinase-like Protein YKL-40 in Patients With Asthma
7. MedImmune Presents New Pharmaco-Economic Data at American Academy of Pediatrics Regarding Infants at High Risk for RSV
8. MedImmune Announces Phase 2 Safety Data for Anti-RSV Antibody and National RSV Surveillance Results
9. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study
10. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
11. Phase 2a Multi-Dose Study Initiated by MedImmune in Patients With Asthma to Further Expand Anti-Interleukin-9 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... DIEGO , Oct. 12, 2017 AVACEN ... recognized the company with their  2017 New Product Innovation Award ... based on extensive primary and secondary medical device market research ... Medical, through its first-to-market OTC, drug-free pain relief product, the ... unique approach to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... , Oct. 12, 2017 West Pharmaceutical ... innovative solutions for injectable drug administration, today announced that ... market opens on Thursday, October 26, 2017, and will ... and business expectations at 9:00 a.m. Eastern Time. To ... 253-336-8738 (International). The conference ID is 94093362. ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... Bethesda, MD (PRWEB) , ... October 12, 2017 , ... ... Award of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s ... 4 – 8. , In honor of Morris F. Collen, a pioneer in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):